## IN THE UNITED STATES PATENT AND TRADMARK OFFICE

blicants: Breitenbach, et al.

fial No.: 10/650,178

Filed: August 28, 2003

Title: SOLID PHARMACEUTICAL

**DOSAGE FORM** 

Case No.: 7113US01

Group Art No.: 1615

Examiner: (not yet assigned)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 on:

Date of Deposit: February 9, 2004

Tanya Parent

Date

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## TRANSMITTAL LETTER

Dear Sir:

Enclosed herewith for the patent application identified above entitled SOLID PHARMACEUTICAL DOSAGE FORM are the following:

- 1. Information Disclosure Statement;
- 2. Form PTO 1449, in duplicate;
- 3. Reference as cited on PTO 1449 (17 reference); and
- 4. Return Receipt Postcard.

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025.

ABBOTT LABORATORIES

Customer Number 23492 Telephone: (847) 935-7835 Facsimile: (847) 938-2623 Respectfully submitted, Breitenbach ét al.

Brettenbagn, et al

Kalim S. Fuzail

Registration No. 45,805 Attorney for Applicants

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

plicants: Breitenbach, et al.

Serial No.: 10/650,178

Filed: August 28, 2003

Title: SOLID PHARMACEUTICAL

**DOSAGE FORM** 

Case No.: 7113US01

Group Art No.: 1615

Examiner: (not yet assigned)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450 on:

Date of Deposit: February 9, 2004

Tanya Parent

Date

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed, to the knowledge of the undersigned, before the mailing date of a first Office Action on the merits. Applicants respectfully petition and request that the Examiner consider the listed documents and evidence such consideration by making appropriate notations on the attached form. Copies of the listed documents are attached.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Commissioner is authorized to charge our Deposit Account any additional fees (or credit any over payments) that may be required under 37 C.F.R. §§ 1.16 and 1.17 in association with this communication for which full payment has not been tendered.

ABBOTT LABORATORIES

Customer Number 23492 Telephone: (847) 935-7835 Facsimile: (847) 938-2623 Respectfully submitted, Breitenbach, et al.

Kalim S. Fuzail

Registration No. 45,805 Attorney for Applicants



DATE: February 9, 2004 SHEET \_1\_ of \_1\_

FORM PTO-1 (Modified)	(PTO-1449 U.S. DEPARTMENT OF COMMERCE fied) PATENT AND TRADEMARK OFFICE					ATTY. DOCKET NO. 7113US01			SERIAL NO. 10/650,178		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					APPLICANT(S) Breitenbach, et al.						
(Use several sheets if necessary) (37 CFR 1.98 (b))					FILING DATE August 28, 2003			1615			
			U.S.PATENT	r DOC	CUMENTS		•				
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INI	VENTOR	CLASS	SUB CLASS	FILI DA			
INITIAL	Al	5,541,206	07/30/1996		of et al.	CLASS	CLASS	DA	I E		
	A2	5,648,497	07/15/1997	Kemp	of et al.						
	A3	5,914,332	06/22/1999	Sham	et al.						
	ļ					<u> </u>	· · · · · · · · · · · · · · · · · · ·				
	FOR	EIGN PATENT O							NC		
		DOCUMENT NUMBER	PUBLIC-ATION DATE	PA	OUNTRY OF TENT OFFICE		SS SUI CLA	SS   LAT	ION ION NO		
-	BI	00/57854	04.10.2000	W	)			X			
	B2	00/74677	14.12.2000	T WC	)				<u> </u>		
	В3	01/00175	04.01.2001	wo	)						
	В4	01/22938	05.04.2001	wo	)						
	В5	01/34118	17.05.2001	- wo	)						
	В6	01/52821	26.07.2001	wc	)		-				
	В7	01/91727	06.12.2001	<del>  w</del> c	)			X			
	B8	02/092595	21.11.2002	wo	)				<u> </u>		
-	В9	95/07696	23.03.1995	W	)						
	B10	98/22106	28.05.1998	W	)				<u> </u>		
	ВП	0942721	22.01.2003	EP			-	<del> </del>	+		
<del></del> -	B12	0732923	12.12.2001	EP					$\vdash$		
		OTHER DOCUME	ENTC		Tid D				<u> </u>		
	CI	Aungst et al., "Am soluble HIV protea Pharmaceutics 156	phiphilic vehic se inhibitor at	les im	prove the o	ral bioava	ilability o	f a poor	ly		
	C2	Chiou et al., "Phari Sci. 60(9):1281-13	naceutical app	licatio	ns of solid	dispersior	systems,	" J. Pha	rm.		
EXAMINER				TDA	TE CONSID	ERED					
AANHINEK: not considered	annare d. Inclu	itation considered. Draw de copy of this form with	next communicat	uon II n ion to ai	υι in contorma pplicant.	ince and					

(Form PTO 1449)